Report of Foreign Issuer (6-k)
29 April 2016 - 9:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2016
Commission File Number 001-36866
SUMMIT
THERAPEUTICS PLC
(Translation of registrants name into English)
85b Park Drive
Milton
Park, Abingdon
Oxfordshire OX14 4RY
United Kingdom
(Address
of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
FORM
20-F
x
FORM 40-F
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):
¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7):
¨
Indicate by check mark whether the registrant by furnishing the information
contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
YES
¨
NO
x
If Yes is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
On April 28, 2016, Summit Therapeutics plc (the Company) issued a press release announcing that
the U.S. Patent and Trademark Office has granted the Company a composition of matter patent for ridinilazole, its product candidate for the treatment of
Clostridium difficile
infection. The related press release is attached hereto as Exhibit
99.1.
The information in this Report on Form 6-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a
filing.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
|
|
|
SUMMIT THERAPEUTICS PLC
|
|
|
By:
|
|
/s/ Erik Ostrowski
|
|
|
Erik Ostrowski
|
|
|
Chief Financial Officer
|
Date: April 28, 2016
EXHIBIT INDEX
|
|
|
Exhibit
Number
|
|
Description
|
|
|
99.1
|
|
Press release dated April 28, 2016
|
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Historical Stock Chart
From Oct 2023 to Oct 2024